EU MDR Article 62 Legal Representative vs. US FDA IDE Sponsor: What Transfers and What Does Not

The rule that shapes everything: 21 CFR 812.18(a)

If your company is headquartered outside the United States and you want to run an investigational device exemption (IDE) study with FDA, one regulation stops many international teams cold. Under 21 CFR 812.18(a), FDA states that 'if a sponsor is not residing or maintaining a place of business in the United States, the sponsor shall furnish the name and address of a person residing or maintaining a place of business in the United States to whom FDA may transmit correspondence and to whom the sponsor shall ensure FDA may transmit correspondence.' In practice, this requirement means a non US company cannot simply submit an IDE application in its own name and walk away. A US person or entity must assume every sponsor obligation listed in Part 812, and that is a materially different role from anything your EU infrastructure already provides.

Distinguishing the EU MDR Article 62 legal representative from the US Part 812 sponsor

An EU MDR Article 62 legal representative is established in a European Union member state and carries accountability to competent authorities within that regulatory jurisdiction for a clinical investigation conducted under the MDR framework. A US Part 812 sponsor, by contrast, is accountable directly to FDA for every element of an IDE study conducted on US soil or involving US subjects, including application submissions, investigator oversight, adverse event reporting, and recordkeeping. The two roles exist in separate legal systems, serve different regulators, and neither satisfies nor substitutes for the other. Holding an EU legal representative arrangement does not transfer any Part 812 obligation off your shoulders in the United States.

What an EU Article 62 legal representative actually does

Under MDR Article 62, the legal representative for a clinical investigation is the entity or individual formally designated in an EU member state to act on behalf of a sponsor that is not established in the Union. This representative interacts with the relevant national competent authority, supports submission of the clinical investigation application through the European database (EUDAMED where applicable), and may carry responsibility for certain regulatory communications within that jurisdiction.

That accountability is real and meaningful inside Europe. It reflects the MDR's intent to ensure that a reachable, legally responsible party exists within the EU regulatory perimeter. However, the moment your investigation crosses the Atlantic and touches an FDA regulated context, that entire framework is jurisdictionally silent. FDA does not recognize an EU legal representative as satisfying the US contact or sponsorship requirement. The obligations under 21 CFR Part 812, including IDE preparation and submission, investigator selection, monitoring, sponsor recordkeeping, and safety reporting to FDA, rest entirely on whoever accepts the US sponsor role.

Why this distinction matters operationally for non US device companies

Many medical device startup founders and regulatory affairs professionals at non US companies assume, reasonably but incorrectly, that because they have already appointed a legal representative for their European clinical work, their regulatory infrastructure can be extended to cover a US study. The logic feels intuitive. The regulatory reality is the opposite.

FDA's IDE framework under Part 812 imposes affirmative, ongoing obligations on the US sponsor throughout the life of the study. These include preparing a complete IDE application, maintaining device accountability records, submitting progress and final reports, and responding to any FDA inquiries through a US contact. A nonsignificant risk device study may operate under abbreviated IDE requirements, but the sponsor identification and US presence requirement under 812.18(a) still applies.

Companies that attempt to route FDA correspondence through a non US headquarters, or that name a foreign legal representative as their US contact, create a structural compliance gap that FDA will identify at the outset. The consequence is typically a deficiency letter, a delayed study start, or a requirement to restructure the entire submission before FDA will engage substantively.

Understanding how these roles differ in depth is covered further at adbccro.com/us-sponsor-representation-vs-sponsor-of-record. If you are still assessing which model applies to your program, the decision framework at adbccro.com/us-sponsor-decision-tool is a practical starting point.

Where ADB fits: a US firm serving non US sponsors from the United States

ADB Consulting and CRO Inc. is a US regulatory consulting firm. Our practice groups review IDE programs, prepare submissions, and assess sponsor obligations under Part 812 on behalf of non US companies seeking to conduct clinical investigations in the United States. We operate from the United States and do not claim EU legal representative status, in country EU presence, or any EU specific regulatory function. We do not advise on EU deadlines, EU fees, or EU competent authority interactions. Our scope is US regulatory affairs, US IDE strategy, and US sponsor accountability under FDA jurisdiction.

Non US companies working with ADB do so because they need a credible, US resident sponsor of record who understands Part 812 from the inside. For more on our international client services, visit adbccro.com/international.

ADB Consulting and CRO Inc. serves as US Sponsor of Record for non US medical device companies conducting FDA regulated investigations under 21 CFR Part 812.

If you are ready to review your IDE pathway or assess how US sponsor obligations apply to your specific program, book a free discovery call with ADB's regulatory team at adbccro.com. Our practice directors work directly with non US sponsors at every stage of the process, from initial feasibility review through IDE submission and study closure.

Reviewed November 11, 2026 by ADB's regulatory team.

Frequently asked questions

Can our EU MDR Article 62 legal representative also serve as our US IDE sponsor under 21 CFR 812.18(a)?

No. An EU MDR Article 62 legal representative is established within the European Union and carries obligations to EU competent authorities under the MDR framework. That role is jurisdictionally confined to Europe. Under 21 CFR 812.18(a), FDA requires a person or entity that resides or maintains a place of business in the United States to carry every sponsor obligation under Part 812. These are two separate legal constructs under two separate regulatory systems. One does not substitute for the other, and FDA will not accept a foreign legal representative as satisfying the US sponsor or US contact requirement.

What specific obligations does a US Part 812 sponsor carry that a non US company cannot handle directly?

A US Part 812 sponsor is responsible for preparing and submitting the IDE application to FDA, selecting and evaluating qualified investigators, ensuring investigational plan compliance, maintaining sponsor records, submitting progress reports and a final report, and reporting unanticipated adverse device effects. All correspondence with FDA on these matters must flow through the US sponsor. A non US company that tries to manage these obligations from outside the United States without a designated US sponsor creates a compliance gap that FDA will flag during its review of the IDE application.

How does ADB assess whether a device program qualifies as nonsignificant risk versus significant risk before IDE submission?

ADB's regulatory team reviews the device description, intended use, subject population, and study design against FDA's criteria for nonsignificant risk determinations as described in FDA guidance on significant and nonsignificant risk device studies. We prepare a risk classification rationale that your IRB can review as part of its independent determination. If the program is significant risk, we assess the full IDE submission pathway under Part 812 and prepare the application accordingly. This review process is part of our standard pre submission engagement and is designed to surface classification questions before they delay your study start.

If this applies to your program, U.S. Market Entry for Non-U.S. Device Manufacturers walks through the process in detail.